Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Medica

Myelofibrosis (including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF)

Initial criteria

  • age ≥ 18 years

Approval duration

1 year